Lorlatinib received approval for the second- or third-line treatment of ALK-positive metastatic NSCLC (after alectinb or ceritinib failure) on the basis of the results of a phase I trial in a pretreated ALK-positive and ROS1-rearranged patient population. Here, ROS1 is linked to non-small cell lung carcinoma.